Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Forte Biosciences Inc (FBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: FBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $45.67
1 Year Target Price $45.67
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.46% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 118.23M USD | Price to earnings Ratio - | 1Y Target Price 45.67 |
Price to earnings Ratio - | 1Y Target Price 45.67 | ||
Volume (30-day avg) 4 | Beta 2.86 | 52 Weeks Range 4.11 - 28.68 | Updated Date 07/17/2025 |
52 Weeks Range 4.11 - 28.68 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -70.65% | Return on Equity (TTM) -130.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 74267037 | Price to Sales(TTM) - |
Enterprise Value 74267037 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.87 | Shares Outstanding 12213800 | Shares Floating 2900046 |
Shares Outstanding 12213800 | Shares Floating 2900046 | ||
Percent Insiders 9.35 | Percent Institutions 80.32 |
Upturn AI SWOT
Forte Biosciences Inc
Company Overview
History and Background
Forte Biosciences, Inc. was a clinical-stage biopharmaceutical company founded in 2011. It focused on developing therapies for autoimmune diseases and inflammatory skin conditions. In September 2022, the company ceased operations after a failed Phase 2 trial of its lead drug candidate, FB-401. The company was later acquired by and became a subsidiary of Cassava Sciences Inc. in October 2022
Core Business Areas
- Drug Development: Forte Biosciences focused on developing and testing FB-401, a live biotherapeutic for atopic dermatitis.
Leadership and Structure
Prior to the acquisition by Cassava Sciences, Forte Biosciences was led by CEO Paul Wagner and had a typical biotech organizational structure with departments focused on research, clinical development, and business operations. It is now a subsidiary of Cassava Science. It is unclear if this continues to exist or not.
Top Products and Market Share
Key Offerings
- FB-401: FB-401 was Forte Biosciences' lead drug candidate, a live biotherapeutic being developed for the treatment of atopic dermatitis. Market share data specific to FB-401 is unavailable because it did not receive FDA approval. Potential competitors included companies with approved treatments for atopic dermatitis, such as Sanofi (SNY) and Regeneron (REGN) with Dupixent.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and focused on developing and commercializing new therapies. The atopic dermatitis market is a significant area of focus, with multiple companies pursuing novel treatments.
Positioning
Forte Biosciences aimed to position FB-401 as a novel, microbiome-based therapy for atopic dermatitis, differentiating itself from existing treatments. Cassava Sciences may or may not continue this path.
Total Addressable Market (TAM)
The global atopic dermatitis market was estimated at billions of USD. Forte Biosciences aimed to capture a portion of this market with FB-401, but this is unachievable since they ceased operations.
Upturn SWOT Analysis
Strengths
- Novel microbiome-based approach
- Focus on unmet medical needs
- Prior clinical trial data (although ultimately unsuccessful)
Weaknesses
- Failed Phase 2 trial of FB-401
- Limited financial resources before acquisition
- No approved products
Opportunities
- Potential for future development programs under Cassava Sciences
- Exploring other indications for FB-401
- Partnerships and collaborations
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial risks
Competitors and Market Share
Key Competitors
- SNY
- REGN
Competitive Landscape
Forte Biosciences faced intense competition from established pharmaceutical companies with approved atopic dermatitis treatments.
Major Acquisitions
Cassava Sciences
- Year: 2022
- Acquisition Price (USD millions): 18
- Strategic Rationale: Cassava Sciences acquired Forte Biosciences to potentially use its assets or intellectual property for their own therapeutic programs, although specific details are not publicly available.
Growth Trajectory and Initiatives
Historical Growth: Forte Biosciences experienced no revenue growth due to its status as a clinical-stage company.
Future Projections: Unclear. Future growth depends on Cassava Sciences' plans for the former Forte Biosciences assets.
Recent Initiatives: Acquisition by Cassava Sciences.
Summary
Forte Biosciences was a clinical-stage biopharmaceutical company that ceased operations after a failed clinical trial. The company was subsequently acquired by Cassava Sciences. Prior to its demise, Forte Biosciences was focused on a novel microbiome approach to treating atopic dermatitis. Its future direction and prospects now depend entirely on Cassava Sciences' strategic decisions. The failure of FB-401 severely impacted the company's value and led to its acquisition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Press Releases
- Cassava Sciences website
Disclaimers:
The information provided is based on publicly available data and may not be entirely comprehensive. Market share data is an estimate and may vary. This analysis is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Forte Biosciences Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2017-04-13 | CEO, President & Chairman Dr. Paul A. Wagner Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.fortebiorx.com |
Full time employees 14 | Website https://www.fortebiorx.com | ||
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.